Evidence map›Paper›PMID 31431050›Full record

ArticleCirculation. Arrhythmia and electrophysiology2019

Assessment of the 2017 AHA/ACC/HRS Guideline Recommendations for Implantable Cardioverter-Defibrillator Implantation in Cardiac Sarcoidosis.

Felipe Kazmirczak, Ko-Hsuan Amy Chen, Selcuk Adabag, Lisa von Wald, Henri Roukoz, David G Benditt, Osama Okasha, Afshin Farzaneh-Far, Jeremy Markowitz, Prabhjot S Nijjar and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Arrhythmia and electrophysiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 96 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Beyond the Biopsy: Imaging Frontiers in Cardiac Sarcoidosis.Cardiology research and practice · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Deep learning approaches to predict late gadolinium enhancement and clinical outcomes in suspected cardiac sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
    Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Cardiac Sarcoidosis: A Comprehensive Clinical Review.Reviews in cardiovascular medicine · 2024
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Optimal left ventricular ejection fraction in risk stratification of patients with cardiac sarcoidosis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Felipe KazmirczakCardiovascular Division, Department of Medicine (F.K., K.-H.A.C., S.A., L.v.W., H.R., D.G.B., O.O., J.M., P.S.N., P.S.V., S.D., C.S.), University of Minnesota Medical School, Minneapolis.
Ko-Hsuan Amy ChenCardiovascular Division, Department of Medicine (F.K., K.-H.A.C., S.A., L.v.W., H.R., D.G.B., O.O., J.M., P.S.N., P.S.V., S.D., C.S.), University of Minnesota Medical School, Minneapolis.
Selcuk AdabagCardiovascular Division, Department of Medicine (F.K., K.-H.A.C., S.A., L.v.W., H.R., D.G.B., O.O., J.M., P.S.N., P.S.V., S.D., C.S.), University of Minnesota Medical School, Minneapolis.
Lisa von WaldCardiovascular Division, Department of Medicine (F.K., K.-H.A.C., S.A., L.v.W., H.R., D.G.B., O.O., J.M., P.S.N., P.S.V., S.D., C.S.), University of Minnesota Medical School, Minneapolis.
Henri RoukozCardiovascular Division, Department of Medicine (F.K., K.-H.A.C., S.A., L.v.W., H.R., D.G.B., O.O., J.M., P.S.N., P.S.V., S.D., C.S.), University of Minnesota Medical School, Minneapolis.
David G BendittCardiovascular Division, Department of Medicine (F.K., K.-H.A.C., S.A., L.v.W., H.R., D.G.B., O.O., J.M., P.S.N., P.S.V., S.D., C.S.), University of Minnesota Medical School, Minneapolis.
Osama OkashaCardiovascular Division, Department of Medicine (F.K., K.-H.A.C., S.A., L.v.W., H.R., D.G.B., O.O., J.M., P.S.N., P.S.V., S.D., C.S.), University of Minnesota Medical School, Minneapolis.
Afshin Farzaneh-FarSection of Cardiology, Department of Medicine, University of Illinois at Chicago (A.F.-F.).
Jeremy MarkowitzCardiovascular Division, Department of Medicine (F.K., K.-H.A.C., S.A., L.v.W., H.R., D.G.B., O.O., J.M., P.S.N., P.S.V., S.D., C.S.), University of Minnesota Medical School, Minneapolis.
Prabhjot S NijjarCardiovascular Division, Department of Medicine (F.K., K.-H.A.C., S.A., L.v.W., H.R., D.G.B., O.O., J.M., P.S.N., P.S.V., S.D., C.S.), University of Minnesota Medical School, Minneapolis.
Pratik S VelangiCardiovascular Division, Department of Medicine (F.K., K.-H.A.C., S.A., L.v.W., H.R., D.G.B., O.O., J.M., P.S.N., P.S.V., S.D., C.S.), University of Minnesota Medical School, Minneapolis.
Maneesh BhargavaDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine (M.B., D.P.), University of Minnesota Medical School, Minneapolis.
David PerlmanDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine (M.B., D.P.), University of Minnesota Medical School, Minneapolis.
Sue DuvalCardiovascular Division, Department of Medicine (F.K., K.-H.A.C., S.A., L.v.W., H.R., D.G.B., O.O., J.M., P.S.N., P.S.V., S.D., C.S.), University of Minnesota Medical School, Minneapolis.
Mehmet AkçakayaDepartment of Electrical and Computer Engineering, Center for Magnetic Resonance Research, University of Minnesota, Minneapolis (M.A.).
Chetan ShenoyCardiovascular Division, Department of Medicine (F.K., K.-H.A.C., S.A., L.v.W., H.R., D.G.B., O.O., J.M., P.S.N., P.S.V., S.D., C.S.), University of Minnesota Medical School, Minneapolis.
Norwegian Womens Public Health Association · NOUniversity of Minnesota Medical Center · USFoundation for Agronomic Research · USMinneapolis VA Health Care System · USResonance Research (United States) · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Institutional Career Development CoreKL2TR002492 · NCATS · UNIVERSITY OF MINNESOTA · PI INGBAR, DAVID H · 2018 to 2022
$6.3M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)KL2TR000113 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$5.4M
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related CardiotoxicityK23HL132011 · NHLBI · UNIVERSITY OF MINNESOTA · PI SHENOY, CHETAN N · 2016 to 2020
$884k
Novel Accelerated Contrast-Enhanced High Resolution Coronary MRIR00HL111410 · NHLBI · UNIVERSITY OF MINNESOTA · PI AKCAKAYA, MEHMET · 2015 to 2017
$746k
NCATS NIH HHS KL2 TR000113NCATS NIH HHS KL2 TR002492NCATS NIH HHS UL1 TR000114NCATS NIH HHS UL1 TR002494NHLBI NIH HHS K23 HL132011NHLBI NIH HHS R00 HL111410
6 · The paper itself

Abstract

backgroundImplantable cardioverter-defibrillators are used to prevent sudden cardiac death in patients with cardiac sarcoidosis. The most recent recommendations for implantable cardioverter-defibrillator implantation in these patients are in the 2017 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. These recommendations, based on observational studies or expert opinion, have not been assessed. We aimed to assess them.

methodsWe performed a large retrospective cohort study of patients with biopsy-proven sarcoidosis and known or suspected cardiac sarcoidosis that underwent cardiovascular magnetic resonance imaging. Patients were followed for a composite end point of significant ventricular arrhythmia or sudden cardiac death. The discriminatory performance of the Guideline recommendations was tested using time-dependent receiver operating characteristic analyses. The optimal cutoff for the extent of late gadolinium enhancement predictive of the composite end point was determined using the Youden index.

resultsIn 290 patients, the class I and IIa recommendations identified all patients who experienced the composite end point during a median follow-up of 3.0 years. Patients meeting class I recommendations had a significantly higher incidence of the composite end point than those meeting class IIa recommendations. Left ventricular ejection fraction (LVEF) >35% with >5.7% late gadolinium enhancement on cardiovascular magnetic resonance imaging was as sensitive as and significantly more specific than LVEF >35% with any late gadolinium enhancement. Patients meeting 2 class IIa recommendations, LVEF >35% with the need for a permanent pacemaker and LVEF >35% with late gadolinium enhancement >5.7%, had high annualized event rates. Excluding 2 class IIa recommendations, LVEF >35% with syncope and LVEF >35% with inducible ventricular arrhythmia, resulted in improved discrimination for the composite end point.

conclusionsWe assessed the Guideline recommendations for implantable cardioverter-defibrillator implantation in patients with known or suspected cardiac sarcoidosis and identified topics for future research.

Indexed as

American Heart AssociationPractice Guidelines as TopicSocieties, MedicalBiopsyCardiomyopathiesDeath, Sudden, CardiacDefibrillators, ImplantableFemaleFollow-Up StudiesHumansMagnetic Resonance Imaging, CineMaleMiddle AgedPrognosisRetrospective StudiesSarcoidosisguidelinehumansmagnetic resonance imagingROC curvesarcoidosisscarUnited States

Identifiers

PMID31431050
PMCPMC6709696
OpenAlexW2969808184

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.